Sellas Life Sciences: A 41% Survival Benefit, a $40 Target and a $150 Million Share Sale
Published on 11/20/2026 at 17:41 | Editorial boerse-global.deSellas Life Sciences has spent the week answering two very different questions — one about biology, the other about capital — and the market has responded to each on its own terms. Shares slipped 5.9% on Friday afternoon after the company fixed the terms of a public offering, a reminder that clinical momentum and financing costs travel in separate lanes.
The Financing: Terms Set, Not Yet Closed
Sellas priced its offering at $13.00 per share, placing roughly 11.5 million newly issued shares — 11,538,462 to be exact. The company expects gross proceeds of $150.0 million before fees and expenses. The accompanying banks hold a 30-day option on up to 1,730,769 additional shares, a standard feature of the offer rather than an exercised allotment. Closing was expected Friday, subject to customary conditions.
The distinction between a fixed offer price and a completed capital raise matters here. A pricing announcement describes the terms for new stock; an expected gross figure is not yet a reported cash inflow. New shares mean fresh capital in exchange for additional ownership rights — neither a standalone burden nor an automatic victory.
Should investors sell immediately? Or is it worth buying Sellas Life Sciences?
The Clinical Readout Behind the Move
Wednesday's news was the engine driving sentiment this week. Sellas reported positive topline results from its Phase III REGAL trial of galinpepimut-S in acute myeloid leukemia. Median overall survival came in at 24.0 months against 14.7 months for the best available treatment, a reduction in the risk of death that the company put at 41%. The primary endpoint on overall survival was met, with a hazard ratio of 0.59 and a p-value of 0.035.
That gives the discussion a concrete clinical foundation — a reported trial result, not merely the promise of future data. Sellas now plans talks with the FDA on an accelerated submission strategy while preparing a potential Biologics License Application, with the first half of 2027 named as the window for that filing. A positive study and an approval remain distinct milestones; collapsing the two turns progress into a finished process.
The Analyst's Verdict
Maxim Group's Jason McCarthy raised his price target to $40 from $30 on Tuesday, reaffirming his buy rating on the back of the REGAL announcement. The upgrade captures how favorably one research house views the data, yet it substitutes for neither the FDA discussions nor the application preparation. A price target is an analyst's assessment and belongs in a different category from a clinical endpoint.
The right lens, then, is not to pit the financing against the science but to keep them cleanly separated before weighing them together. Sellas has delivered positive survival data and locked in the terms of a share sale. The next test lies in how the company advances the regulatory path it has laid out.
Ad
Sellas Life Sciences Stock: New Analysis - 20 November
Fresh Sellas Life Sciences information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
